Comparison of pretreatment complement biomarkers obtained from 19 patients with clinically diagnosed aHUS vs a cohort of 38 patients with ADAMTS13-deficient TTP
| Clinical diagnosis . | Complement biomarkers (ng/mL) . | ||||
|---|---|---|---|---|---|
| Factor Bb (244.3-960.8) . | C4d (278.5-1845.9) . | C5b-9 (33.9-238.2) . | C5a (18.6-47.9) . | C3a (6.9-242.3) . | |
| Acquired TTP*6 (n = 38) | 2153 (343-5448) | 3534 (458-7450) | 585 (210-1924) | 75 (29-210) | 777 (128-4782) |
| aHUS* (n = 19) | 7386 (603-30 610) | 2914 (1394-15 210) | 1098 (422-4840) | 115 (55-280) | 1237 (79-13 730) |
| P value† | .063 | .706 | < .0001 | .004 | .031 |
| Clinical diagnosis . | Complement biomarkers (ng/mL) . | ||||
|---|---|---|---|---|---|
| Factor Bb (244.3-960.8) . | C4d (278.5-1845.9) . | C5b-9 (33.9-238.2) . | C5a (18.6-47.9) . | C3a (6.9-242.3) . | |
| Acquired TTP*6 (n = 38) | 2153 (343-5448) | 3534 (458-7450) | 585 (210-1924) | 75 (29-210) | 777 (128-4782) |
| aHUS* (n = 19) | 7386 (603-30 610) | 2914 (1394-15 210) | 1098 (422-4840) | 115 (55-280) | 1237 (79-13 730) |
| P value† | .063 | .706 | < .0001 | .004 | .031 |
Compared with the acquired TTP patients, patients clinically diagnosed aHUS tended to have significantly higher C5b-9 and C5a levels. P values reflect comparisons of complement biomarkers between diagnosis groups using Wilcoxon rank sum tests. Bolded text signifies the values that were statistically significant at the P < .05 level.
For the acquired TTP patients, the mean data for each complement biomarker are shown; whereas for the smaller aHUS cohort, the median biomarker data are presented.
Compared with the 19 clinically diagnosed aHUS patients. The Mann-Whitney independent U test was used for the Bb and C4d comparisons, whereas a generalized linear model was used to compare C5b-9, C5a, and C3a, using age, sex, and race as covariables.